Literature DB >> 33096991

Massive pericardial effusion and cardiac tamponade revealed undiagnosed Turner syndrome: a case report.

Wei Qiang1, Rongxin Sun2, Xiaopu Zheng3, Yuan Du4.   

Abstract

BACKGROUND: Patients with Turner syndrome (TS) are prone to autoimmune disorders. Although most patients with TS are diagnosed at younger ages, delayed diagnosis is not rare. CASE
PRESENTATION: A 31-year-old woman was presented with facial edema, chest tightness and dyspnea. She had primary amenorrhea. Physical examination revealed short stature, dry skin and coarse hair. Periorbital edema with puffy eyelids were also noticed with mild goiter. Bilateral cardiac enlargement, distant heart sounds and pulsus paradoxus, in combination with hepatomegaly and jugular venous distention were observed. Her hircus and pubic hair was absent. The development of her breast was at 1st tanner period and gynecological examination revealed infantile vulva. Echocardiography suggested massive pericardial effusion. She was diagnosed with cardiac tamponade based on low systolic pressure, decreased pulse pressure and pulsus paradoxus. Pericardiocentesis was performed. Thyroid function test and thyroid ultrasound indicated Hashimoto's thyroiditis and severe hypothyroidism. Sex hormone test revealed hypergonadotropin hypogonadism. Further karyotyping revealed a karyotype of 45, X [21]/46, X, i(X) (q10) [29] and she was diagnosed with mosaic + variant type of TS. L-T4 supplement, estrogen therapy, and antiosteoporosis treatment was initiated. Euthyroidism and complete resolution of the pericardial effusion was obtained within 2 months.
CONCLUSION: Hypothyroidism should be considered in the patients with pericardial effusion. The association between autoimmune thyroid diseases and TS should be kept in mind. Both congenital and acquired cardiovascular diseases should be screened in patients with TS.

Entities:  

Keywords:  Autoimmune thyroid disease; Cardiac tamponade; Hypothyroidism; Pericardial effusion; Turner syndrome

Year:  2020        PMID: 33096991      PMCID: PMC7583196          DOI: 10.1186/s12872-020-01728-2

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


Background

Turner syndrome (TS) is a rare condition with short stature, ovarian dysgenesis and infertility in women as the result of either complete or partial loss of one X chromosome. TS is also associated congenital heart malformations, metabolism disorders such as diabetes mellitus and osteoporosis. Patients with TS are prone to autoimmune disorders among which Hashimoto’s thyroiditis is the most common one [1]. The average age at diagnosis is around 15 years old, but delayed diagnosis is not rare [2]. Here, we reported woman diagnosed with TS at the age of 31, with initial presentation of massive pericardial effusion and cardiac tamponade due to very severe hypothyroidism. This case emphasized the association between thyroid diseases and TS and also the necessity of a multidisciplinary approach to care.

Case presentation

A 31-year-old woman was presented at cardiovascular department with facial edema for 2 months and chest tightness for 1 week. Fatigue, palpitation and exertional dyspnea were also reported. She had primary amenorrhea. The patient’s vital signs were: T 36.1℃, P 110 bpm, R 20 bpm, BP 80/70 mmHg. She was 141 cm high and weighed 41 kg. Physical examination revealed short stature, dry skin and coarse hair. Periorbital edema with puffy eyelids were also noticed with mild goiter. Bilateral cardiac enlargement, distant heart sounds and pulsus paradoxus, in combination with hepatomegaly and jugular venous distention were observed. There was no pretibial non-pitting edema. Her hircus and pubic hair was absent. The development of her breast was at 1st Tanner period and gynecological examination revealed infantile vulva. The electrocardiogram (ECG) showed low voltage in all leads (Fig. 1a) and the chest X-Ray showed cardiomegaly (Fig. 1b). Massive pericardial effusion was the most protruding finding on echocardiography (33 mm behind the posterior wall of the left ventricle, 6 mm in front of the anterior wall of the right ventricle, 23 mm outside the lateral wall of the left ventricle) (Fig. 1c). The size and structure of the heart were normal and the left ventricular ejection fraction was 63%. Elevated liver enzymes were reported during routine evaluation (Table 1). She was diagnosed with cardiac tamponade based on low systolic pressure, decreased pulse pressure and pulsus paradoxus. Pericardiocentesis was performed and her dyspnea was alleviated after the drainage of pericardial effusion (Additional file 1: Fig. S1). No increases of white blood cell (WBC), percentage of neutrophil or procalcitonin were found (Table 1). Some etiologies for pericardial effusion including tuberculosis, connective tissue diseases and tumors were excluded by measurement of antibodies and biomarkers (Additional file 2: Table S1). Acid-fast staining, bacterial and fungal cultures of the effusion fluid were also negative.
Fig. 1

Cardiovascular findings of the patient at initial admission. a ECG showed low voltage in all precordial leads. b Chest X-ray suggested cardiomegaly. c Transthoracic echocardiography indicated massive pericardial effusion. d Resolution of the pericardial effusion

Table 1

Laboratory findings on admission of the patient

ParametersPatient’s valuesReference range
BMI20.6218–24 kg/m2
Blood pressure
 SBP80≤ 120 mmHg
 DBP70≤ 80 mmHg
Glucose metabolism
 HbA1c5.24.0–6.0%
 Glucose (0 h)4.303.9–6.1 mmol/L
 Glucose (2 h)4.63< 7.8 mmol/L
 Insulin (0 h)11.35.0–25.0 mIU/L
 Insulin (2 h)50.6
Lipid
 Total CHO5.333.1–5.69 mmol/L
 TG1.220.56–1.47 mmol/L
 LDL3.132.07–3.10 mmol/L
 HDL1.781.29–1.55 mmol/L
 Uric acid293155–357 μmol/L
Blood routine
 RBC3.443.8–5.1 * 1012/L
 HGB130110–150 g/L
 WBC5.43.5–9.5 * 109/L
 NEUT%71.840–75%
Liver function
 ALT377–40 IU/L
 AST6213–35 IU/L
 ALP19635–100 IU/L
 GGT2397–45 IU/L
Renal function
 BUN5.42.6–7.5 mmol/L
 CRE7541–81 μmol/L
Electrolytes
 Na138137–147 mmol/L
 K3.463.5–5.3 mmol/L
 Cl85.696–108 mmol/L
Hydropericardium
 CHO2.203.1–5.69 mmol/L
 Rivalta reactionPositiveNegative

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; CHO, cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; RBC, red blood cell; HGB, hemoglobin; WBC, white blood cell; NEUT%, neutrophil ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-Glutamyl transferase; BUN, blood urea nitrogen; CRE, creatinine; Na, sodium; K, potassium; Cl, chloride

Cardiovascular findings of the patient at initial admission. a ECG showed low voltage in all precordial leads. b Chest X-ray suggested cardiomegaly. c Transthoracic echocardiography indicated massive pericardial effusion. d Resolution of the pericardial effusion Laboratory findings on admission of the patient BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; CHO, cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; RBC, red blood cell; HGB, hemoglobin; WBC, white blood cell; NEUT%, neutrophil ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-Glutamyl transferase; BUN, blood urea nitrogen; CRE, creatinine; Na, sodium; K, potassium; Cl, chloride Thyroid function indicated severe hypothyroidism with positive TPOAb (Table 2). Further thyroid ultrasound revealed diffuse inhomogeneous hypo-echoic area. The diagnosis of Hashimoto thyroiditis was made. In view of primary amenorrhea, short stature and the absence of the secondary sexual characteristics, Turner syndrome (TS) was under suspicion. Pelvic ultrasound and sex hormone test were arranged, and absent ovaries, infantile uterus, decreased estrogen and elevated follicle stimulating hormone (FSH) were reported. Further karyotyping of peripheral blood cells revealed a karyotype of 45, X/46, X, i(X) (q10). The patient was diagnosed with mosaic and variant type of TS. Functions of other endocrine glands were tested and no abnormalities were found. Metabolism of glucose, lipid and uric acid (UA) were also evaluated (Table 1). The bone mineral density (BMD) was assessed and the T value of femur and lumbar vertebra (L1 to L4) were -3.5 and -3.6, respectively. Sensorineural deafness was revealed by electrical audition test.
Table 2

Function of endocrine glands

ParametersPatient’s valuesReference range
Thyroid function on admission
 TPOAba> 3000< 15 U/mL
 TSHa> 1000.25–5 μIU/mL
 T3a< 0.050.78–2.20 ng/mL
 T4a< 2.004.2–13.5 μg/dL
 Free T3a2.942.91–9.08 pmol/L
 Free T4a3.009.05–25.5 pmol/L
 TSHb12.10.25–5 μIU/mL
 Free T3b4.792.91–9.08 pmol/L
 Free T4b19.29.05–25.5 pmol/L
Pituitary–gonadal axis
 E2< 18.428–156 pmol/L
 Prog2.000.7–4.3 nmol/L
 PRL12.844.79–23.3 ng/mL
 LH6.281.7–8.6 mIU/mL
 FSH27.321.5–12.4 mIU/mL
 T< 0.0870.29–1.67 nmol/L
Pituitary-adrenal axis
 ACTH37.97.2–63.3 pg/mL
 COR (8 am)30.85–28 μg/dL
GH/IGF-1
 GH < 1.7 < 10 μg/L
 IGF-1169115–307 ng/mL
 IGF-BP34.233.5–7.0 μg/mL

TPOAb, thyroid peroxidase antibody; TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, thyroxine; E2, estradiol; Prog, progesterone; PRL, prolactin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; T, testosterone; ACTH, adrenocorticotropic hormone; COR, cortisol; GH, growth hormone; IGF-1, insulin-like growth factor 1; IGF-BP3, insulin-like growth factor binding protein 3

aThroid function at presentation

bTSH, FT4 and FT3 after one month of L-T4 sumplement

Function of endocrine glands TPOAb, thyroid peroxidase antibody; TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, thyroxine; E2, estradiol; Prog, progesterone; PRL, prolactin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; T, testosterone; ACTH, adrenocorticotropic hormone; COR, cortisol; GH, growth hormone; IGF-1, insulin-like growth factor 1; IGF-BP3, insulin-like growth factor binding protein 3 aThroid function at presentation bTSH, FT4 and FT3 after one month of L-T4 sumplement Levothyroxine (L-T4) supplement was initiated (25 μg/d for 3 days, 50 μg/d for 1 week and then 75 μg/d). Estrogen therapy and antiosteoporosis treatment were applied. The TSH was 12.1 μIU/mL with a normal FT4 after one month (Table 2). Meanwhile, resolution of the pericardial effusion was observed on echocardiography (Fig. 1d). L-T4 was increased to 112.5 μg/d and euthyroidism was reported one month later on the telephone follow-up.

Discussion and conclusion

Here, we reported woman diagnosed with TS at the age of 31, with initial presentation of massive pericardial effusion and cardiac tamponade due to very severe hypothyroidism. The first difficulty in the diagnosis of this case is to identify that the cause of pericardial effusion is hypothyroidism induced by Hashimoto’s thyroiditis. The etiologies of pericardial effusions are numerous among which hypothyroidism is an uncommon one. The prevalence of pericardial effusion is 3–6% in patients with mild disease and 80% in myxedema [3-5]. It’s revealed during cardiovascular evaluation in most cases, but can also be the initial presentation. Increased capillary permeability and reduced lymphatic drainage result in the gradual accumulation of fluid in the pericardial space, though the mechanism hasn’t been fully elucidated [6]. The process usually takes from months to years, as the severity and chronicity of hypothyroidism varies [5, 7]. Moderate and massive effusions are rare [3, 4]. Pericardiocentesis is not necessary in most cases as pericardial effusion disappear within months on L-T4 treatment, with the exception of cardiac tamponade or for differential diagnosis. The more challenging step was to reveal the underlying TS in this patient after a primary diagnosis of Hashimoto’s thyroiditis and hypothyroidism. This is not only based on her primary amenorrhea and abnormal physical examination, but also based on the alert of increased frequency of Hashimoto’s thyroiditis in patients with TS. As the X chromosome contains several immune-related genes [8], the loss of a distinct X chromosome locus could facilitate the development of autoimmune thyroid diseases (AITDs) [9]. As a result, patients with TS have the tendency to develop various autoimmune diseases, including AITDs, type 1 diabetes and inflammatory bowel disease (IBD), among which Hashimoto’s thyroiditis is the most common one [1]. F. Mortensen et al. and Chen et al. reported the increased frequency of AITDs with age [10, 11]. Besides, though euthyroidism is a common clinical phenotype, transition to subclinical or overt hypothyroidism can occur [12], emphasizing the importance of screening for thyroid diseases through life-span [13]. A higher prevalence of AITDs was reported in iso-chromosome Xq population [14, 15]. Further studies are required to elucidate the underlying mechanism. Despite the well documented role of estrogen in AITDs, no association between estrogen administration and the occurrence of AIDs was revealed in TS patients [9]. Another noteworthy issue is the screening for cardiovascular abnormalities of TS itself. Both congenital heart malformation and acquired disorder such as ischemic heart disease contributes greatly to morbidity and mortality in patients with TS. Bicuspid aortic valve is the most common congenital malformation with a prevalence of 14–34%. Other common phenotypic characteristics of heart include coarctation of the aorta (7–14%) and aortic dilation/aneurysm (3–42%) [2]. These cardiovascular malformations can occur in isolation or in combination in patients with TS [16-19]. Hypertension occurs in 50% of patients with TS [2]. Persistent elevation of systolic blood pressure is a risk factor for aortic root dilation and the consequent aortic dissection. The exact genetic and epigenetic mechanism of cardiopathies in TS remains unclear. Acquired heart abnormalities are associated with obesity, hyperlipidemia, hypertension, diabetes mellitus and low estrogen levels. Cardiovascular diseases, both congenital and acquired ones, should be screened in patients with TS. In conclusion, this case indicated that hypothyroidism should be screened in patients with pericardial effusion, and also emphasized the link between autoimmune thyroid diseases and TS. Additional file 1: Fig. S1. The process of pericardiocentesis under the guidance of ultrasound. a Confirmation of the puncture site. b–d Paracentetic needle in the pericardial cavity. Additional file 2: Table S1. Screening results for other etiologies of pericardial effusion.
  18 in total

1.  Twin studies as a model for exploring the aetiology of autoimmune thyroid disease.

Authors:  Thomas Heiberg Brix; Laszlo Hegedüs
Journal:  Clin Endocrinol (Oxf)       Date:  2012-04       Impact factor: 3.478

2.  Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group.

Authors:  Carolyn A Bondy
Journal:  J Clin Endocrinol Metab       Date:  2006-10-17       Impact factor: 5.958

3.  Pericardial effusion in primary hypothyroidism.

Authors:  U M Kabadi; S P Kumar
Journal:  Am Heart J       Date:  1990-12       Impact factor: 4.749

4.  An isolated Xp deletion is linked to autoimmune diseases in Turner syndrome.

Authors:  Judith Stoklasova; Jirina Zapletalova; Zdenek Frysak; Vaclav Hana; Jan Cap; Marketa Pavlikova; Ondrej Soucek; Jan Lebl
Journal:  J Pediatr Endocrinol Metab       Date:  2019-05-27       Impact factor: 1.634

5.  Cardiovascular malformations and complications in Turner syndrome.

Authors:  V P Sybert
Journal:  Pediatrics       Date:  1998-01       Impact factor: 7.124

6.  Autoimmune thyroid syndrome in women with Turner's syndrome--the association with karyotype.

Authors:  M Elsheikh; J A Wass; G S Conway
Journal:  Clin Endocrinol (Oxf)       Date:  2001-08       Impact factor: 3.478

Review 7.  Turner syndrome: mechanisms and management.

Authors:  Claus H Gravholt; Mette H Viuff; Sara Brun; Kirstine Stochholm; Niels H Andersen
Journal:  Nat Rev Endocrinol       Date:  2019-06-18       Impact factor: 43.330

8.  Increased prevalence of autoimmunity in Turner syndrome--influence of age.

Authors:  K H Mortensen; L Cleemann; B E Hjerrild; E Nexo; H Locht; E M Jeppesen; C H Gravholt
Journal:  Clin Exp Immunol       Date:  2009-02-26       Impact factor: 4.330

9.  Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS).

Authors:  L Mazzanti; E Cacciari
Journal:  J Pediatr       Date:  1998-11       Impact factor: 4.406

Review 10.  Cardiovascular abnormalities in Turner's syndrome: what prevention?

Authors:  Yves Dulac; Catherine Pienkowski; Sylvia Abadir; Maité Tauber; Philippe Acar
Journal:  Arch Cardiovasc Dis       Date:  2008-08-20       Impact factor: 2.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.